Literature DB >> 1987102

Angiotensin II binding receptors in retinal and optic nerve head blood vessels. An autoradiographic approach.

G Ferrari-Dileo1, E B Davis, D R Anderson.   

Abstract

Angiotensin II (AII) binding sites were identified in cross-sections of the cat retinal and optic nerve vasculatures. The authors used 3H-AII and 125I-saralasin, an agonist and a high-affinity antagonist of AII receptors, respectively, to generate light microscopy autoradiograms in resin-embedded tissues. With both radioligands the presence of AII binding sites was confirmed in retinal arterioles but not in the veins or capillaries of the retina. Additionally the presence of such binding sites in the capillaries of the optic nerve head was shown. These results support the hypothesis that microvascular tone and perhaps autoregulatory responses of optic nerve capillaries might be influenced by vasoactive substances, such as AII, either leaking from the choroid or locally synthetized.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1987102

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  11 in total

Review 1.  Retinal vascular image analysis as a potential screening tool for cerebrovascular disease: a rationale based on homology between cerebral and retinal microvasculatures.

Authors:  Niall Patton; Tariq Aslam; Thomas Macgillivray; Alison Pattie; Ian J Deary; Baljean Dhillon
Journal:  J Anat       Date:  2005-04       Impact factor: 2.610

2.  The renin-angiotensin system in the human eye.

Authors:  N J Van Haeringen
Journal:  Br J Ophthalmol       Date:  1996-02       Impact factor: 4.638

Review 3.  Use of isolated ocular arteries in vitro to define the pathology of vascular changes in glaucoma.

Authors:  C H Buckley; P W Hadoke; C J O'Brien
Journal:  Br J Ophthalmol       Date:  1997-07       Impact factor: 4.638

4.  Quantitative receptor autoradiographic analysis for angiotensin II receptors in bovine retinal microvessels: quantitation with radioluminography.

Authors:  T Sato; M Niwa; A Himeno; K Tsutsumi; T Amemiya
Journal:  Cell Mol Neurobiol       Date:  1993-06       Impact factor: 5.046

5.  Angiotensin II-induced hypertension regulates AT1 receptor subtypes and extracellular matrix turnover in mouse retinal pigment epithelium.

Authors:  Françoise Praddaude; Scott W Cousins; Christiane Pêcher; Maria E Marin-Castaño
Journal:  Exp Eye Res       Date:  2009-03-10       Impact factor: 3.467

6.  Regulation of angiotensin II receptors and extracellular matrix turnover in human retinal pigment epithelium: role of angiotensin II.

Authors:  Gary E Striker; Francoiçe Praddaude; Oscar Alcazar; Scott W Cousins; Maria E Marin-Castaño
Journal:  Am J Physiol Cell Physiol       Date:  2008-10-15       Impact factor: 4.249

7.  Common histopathological changes in aged human orbital arteries.

Authors:  E R Büchi; P Schiller; M Felice; A Bunkenburg; B Daicker
Journal:  Int Ophthalmol       Date:  1993-02       Impact factor: 2.031

8.  AT1 receptor characteristics of angiotensin analogue binding in human synovium.

Authors:  D A Walsh; T Suzuki; G A Knock; D R Blake; J M Polak; J Wharton
Journal:  Br J Pharmacol       Date:  1994-06       Impact factor: 8.739

9.  Effects of bisoprolol and cilazapril on the central retinal artery blood flow in patients with essential hypertension--preliminary results.

Authors:  Andrzej Madej; Stanisława Gierek-Ciaciura; Maciej Haberka; Joanna Lekston-Madej; Marcin Basiak; Olga Domańska; Bogusław Okopień
Journal:  Ups J Med Sci       Date:  2010-09-22       Impact factor: 2.384

10.  Losartan Treatment Protects Retinal Ganglion Cells and Alters Scleral Remodeling in Experimental Glaucoma.

Authors:  Harry A Quigley; Ian F Pitha; Derek S Welsbie; Cathy Nguyen; Matthew R Steinhart; Thao D Nguyen; Mary Ellen Pease; Ericka N Oglesby; Cynthia A Berlinicke; Katherine L Mitchell; Jessica Kim; Joan J Jefferys; Elizabeth C Kimball
Journal:  PLoS One       Date:  2015-10-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.